Thus, this adjusted threshold could potentially eliminate the need for FISH in 16/47 of equivocal HER2 IHC 2+ uterine carcinomas in the discovery cohort and 1/6 in the validation cohort, for a total of 17/53 (32.1%) cases. Here, ERBB2 is linked to uterine carcinoma.